Eiropas Savienība - portugāļu - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - agentes antineoplásicos - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Eiropas Savienība - portugāļu - EMA (European Medicines Agency)

gilead sciences ireland uc - ledipasvir, sofosbuvir - hepatite c, crônica - antivirais para uso sistêmico - harvoni is indicated for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 e 5. para o vírus da hepatite c (vhc) genótipo-actividade específica, consulte as secções 4. 4 e 5.

Eiropas Savienība - portugāļu - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. veja as seções 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Eiropas Savienība - portugāļu - EMA (European Medicines Agency)

laboratorios lesvi s.l. - fumarato de dimetilo - esclerose múltipla remitente-recorrente envio - imunossupressores - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Eiropas Savienība - portugāļu - EMA (European Medicines Agency)

corza medical gmbh - fibrinogénio humano, trombina humana - hemostasia, cirúrgica - anti-hemorrágicos - tachosil is indicated in adults and children from 1 month of age for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for suture support in vascular surgery where standard techniques are insufficient. tachosil is indicated in adults for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery (see section 5.

Eiropas Savienība - portugāļu - EMA (European Medicines Agency)

biogen netherlands b.v. - fumarato de dimetilo - esclerose múltipla - imunossupressores - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Eiropas Savienība - portugāļu - EMA (European Medicines Agency)

mylan ireland limited - fumarato de dimetilo - esclerose múltipla remitente-recorrente envio - imunossupressores - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Eiropas Savienība - portugāļu - EMA (European Medicines Agency)

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - fumarato de dimetilo - esclerose múltipla remitente-recorrente envio - imunossupressores - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Eiropas Savienība - portugāļu - EMA (European Medicines Agency)

accord healthcare s.l.u. - leuprorelin mesilate - neoplasias prostáticas - terapia endócrina - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Eiropas Savienība - portugāļu - EMA (European Medicines Agency)

teva gmbh - fumarato de dimetilo - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunossupressores - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).